Goldman Sachs Group Inc Rhythm Pharmaceuticals, Inc. Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
A detailed history of Goldman Sachs Group Inc transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 3,879,796 shares of RYTM stock, worth $241 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,879,796
Previous 5,288,635
26.64%
Holding current value
$241 Million
Previous $217 Million
6.4%
% of portfolio
0.03%
Previous 0.04%
Shares
19 transactions
Others Institutions Holding RYTM
# of Institutions
192Shares Held
67.3MCall Options Held
834KPut Options Held
78.6K-
Primecap Management CO Pasadena, CA7.22MShares$448 Million0.28% of portfolio
-
Black Rock Inc. New York, NY6.74MShares$418 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.4MShares$397 Million3.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.08MShares$377 Million4.44% of portfolio
-
Perceptive Advisors LLC New York, NY3.56MShares$221 Million4.87% of portfolio
About RHYTHM PHARMACEUTICALS, INC.
- Ticker RYTM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,720,000
- Market Cap $3.46B
- Description
- Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...